Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $53.6 million.

  • Mirum Pharmaceuticals' Net Cash Flow rose 62556.68% to $53.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.9 million, marking a year-over-year increase of 17119.9%. This contributed to the annual value of -$62.1 million for FY2024, which is 13919.13% down from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Net Cash Flow of $53.6 million as of Q3 2025, which was up 62556.68% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Net Cash Flow ranged from a high of $147.9 million in Q2 2023 and a low of -$69.2 million during Q2 2024
  • For the 5-year period, Mirum Pharmaceuticals' Net Cash Flow averaged around $7.3 million, with its median value being $1.3 million (2021).
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Net Cash Flow skyrocketed by 153541.18% in 2023, and later plummeted by 26578.26% in 2024.
  • Mirum Pharmaceuticals' Net Cash Flow (Quarter) stood at $75.5 million in 2021, then crashed by 110.39% to -$7.8 million in 2022, then plummeted by 114.78% to -$16.8 million in 2023, then surged by 105.42% to $913000.0 in 2024, then skyrocketed by 5765.28% to $53.6 million in 2025.
  • Its Net Cash Flow stands at $53.6 million for Q3 2025, versus $14.1 million for Q2 2025 and -$11.7 million for Q1 2025.